Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... AxioMx Inc. ... the National Institutes of Health (NIH) has awarded the company a Phase I ... NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. AxioMx will use ...
(Date:9/1/2015)... ... September 01, 2015 , ... Leading CEOs, CSOs, ... pain management space join prominent academics and key investors for Neuro Advance Boston, ... School in Boston. , Neuro Advance Boston focuses on the latest developments ...
(Date:9/1/2015)... ... September 01, 2015 , ... Industry leader iLab ... Pacific. In this newly-created position, Gibbs will lead iLab’s business operations in the ... of tools. This entails not only introducing iLab to potential partners but support ...
(Date:9/1/2015)... ... September 01, 2015 , ... GenoCAD, ... a groundbreaking new version of its flagship DNA design platform, which has been ... DNA sequences into numerous genetic parts, which in turn can be recombined using ...
Breaking Biology Technology:AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2
... July 21, 2011 The U.S. Food & Drug ... a clinical trial for gene therapy for a rare ... and London, this trial based on preclinical research performed ... gene therapy product, is now going to be launched ...
... July 21, 2011 Advanced Cell Technology, Inc. ("ACT"; ... medicine, announced today that it has entered into an ... Biotech"), a leading South Korea-based biotechnology company, designed to ... venture, Stem Cell & Regenerative Medicine International (SCRMI).  Under ...
... DURHAM, N.C. Researchers at Duke University Medical Center ... of Chlamydia , the bacteria responsible for the ... States. The team, which included Duke University ... the bacteria,s self-defense mechanisms. The therapies that ...
Cached Biology Technology:Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 2Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 3Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 4Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 5ACT Obtains Exclusive License for Hemangioblast Technology in North America 2ACT Obtains Exclusive License for Hemangioblast Technology in North America 3ACT Obtains Exclusive License for Hemangioblast Technology in North America 4ACT Obtains Exclusive License for Hemangioblast Technology in North America 5Newly designed molecule blocks chlamydia bacteria 2Newly designed molecule blocks chlamydia bacteria 3
(Date:8/28/2015)... -- According to a new market research ... (Pen & Paper Based, Hosted, Biometrics), Service, Application (Clinical ... Vertical and Region - Global Forecast to 2020", published ... from USD 2.4 Billion in 2015 to USD 7.5 ... (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)... August 24, 2015 The consulting company ... largest biometrics manufacturer DERMALOG and its customized solutions and products ... Biometrics Company of the Year Award". DERMALOG is particularly successful ... .   -Cross reference: Picture is available at ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... STATION Researchers at Texas A&M University have confirmed for ... off the Texas coast for at least the past 23 ... to marine life in the area. Steve DiMarco, associate ... dead zones in the Gulf of Mexico for more than ...
... fresh evidence that urbanization in the United States threatens the ... six-year study also refutes one of the most widely accepted ... kinds of birds. Most ecologists have assumed that common ... and raccoons were destroying eggs or killing young birds ...
... Md., April 1, 2008 The U.S. Pharmacopeial (USP) ... dissolution variability of USP Prednisone Lot P Reference Standard ... less variability in USP Prednisone Lot P tablets than ... dosage forms plays a critical role in drug manufacturing ...
Cached Biology News:Researchers confirm dead zone off Texas coast since 1985 2Some migratory birds can't find success in urban areas, study finds 2Some migratory birds can't find success in urban areas, study finds 3Prednisone tablets less variable than marketed drugs 2
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: